LISATA THERAPEUTICS, INC. — Director's Dealing 2014

Aug 1, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2014-08-01

Reporting Person: Smith Robin L (Chairman of the Board and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-08-01	Stock Option (right to purchase)	$6.21	A	75000	Acquired	2024-07-31	Common Stock, par value $0.001 per share (75000)	Direct

Footnotes

F1: On August 1, 2014, the Reporting Person was granted an option (the "Option") to purchase 75,000 shares of the Issuer's common stock (the "Option Shares"), $.001 par value (the "Common Stock"), subject to all terms and conditions of the Issuer's 2009 Amended & Restated Equity Compensation Plan (the "Plan"). The Option was fully vested upon grant. The award was approved by the Compensation Committee as a bonus for the successful completion of the acquisition of California Stem Cell, Inc. ("CSC") by the Issuer.